Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Induction of the MYC oncogene increases the ML-792-mediated viability effect in cancer cells
Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines
Smiles: CC(C)(C)NCC(O)C1C=C(CO)C(O)=CC=1
Smiles: CC(C)NC(=O)COC1=CC(=CC=C1)C1N=C(NC2C=C3C=NNC3=CC=2)C2=CC=CC=C2N=1
4 μM in HIF-1α nuclear translocation assay
Lenalidomide Catalog No.:M8013-2 Induction of the MYC oncogeneLenalidomide, also known as CC 5013, is the thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Lenalidomide is an approved drug. Product information CAS